NO20051291L - Bredspektrede substituerte oksindol-sulfonamid HIV-proteaseinhibitorer - Google Patents

Bredspektrede substituerte oksindol-sulfonamid HIV-proteaseinhibitorer

Info

Publication number
NO20051291L
NO20051291L NO20051291A NO20051291A NO20051291L NO 20051291 L NO20051291 L NO 20051291L NO 20051291 A NO20051291 A NO 20051291A NO 20051291 A NO20051291 A NO 20051291A NO 20051291 L NO20051291 L NO 20051291L
Authority
NO
Norway
Prior art keywords
alkyl
protease inhibitors
cycloalkyl
hiv protease
wide
Prior art date
Application number
NO20051291A
Other languages
English (en)
Other versions
NO331846B1 (no
Inventor
Piet Tom Bert Paul Wigerinck
Abdellah Tahri
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of NO20051291L publication Critical patent/NO20051291L/no
Publication of NO331846B1 publication Critical patent/NO331846B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Substituerte oksindol-sulfonamid HIV-. proteaseinhibitorer.oreliggende oppfinnelse vedrører forbindelsene med. formelen. N-oksider, salter, stereoisomere former, racemiske blandinger, promedikamenter, estere og metabolitter derav, hvori Ri og Rhver er H, eventuelt substituert C-alkyl, C.alkenyl, C-cykloalkyl, aryl. Ht, HetRi kan også være et radikal med formel (RiuRub) NC (R10lRiob) CR9-; t er 0, 1 eller 2; Rer H eller C_alkyl; L er -C(=0)-, -0-C{=0)-, -NRa-C (=0) -, -0-Ci-6alkandiyl-C(=0) -, -NR-C-alkandiyl-C(=0)-, -S(=0)-, -0-S(=0)-, -NR-S(=0); Rer Ci-6alkyl, aryl, C.cykloalkyl, C-cykloalkylC-alkyl, eller arylC--alkyl; Rt er H, C1.<alkylOC(=0) , karboksyl, aminoC(=0) , mono- eller di (Cnalkyl) aminoC (=0) , C.cykloalkyl, C.-alkenyl, C.alkynyl eller eventuelt substituert C-alkyl;. Rog Rer C.alkenyl, C.alkynyl, C3_7cykioalkyl eller C-(alkyl, eventuelt substituert på et eller flere atomer; Rog Rkan også være hydrogen, aryl, Het, Het; Rér hydrogen eller C_alkyl eventuelt substituert på et eller flere karbonatomer. Den vedrører videre deres anvendelse som HIV-proteaseinhibitorer i et vidt spekter, fremgangsmåter ved deres fremstilling samt farmasøytiske sammensetninger og diagnostiske utstyrssett omfattende dem. Den vedrører også kombinasjoner derav med et annet anti-
NO20051291A 2002-08-14 2005-03-14 Bredspektrede, substituerte oksindol-sulfonamid HIV-proteaseinhibitorer. NO331846B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02078384 2002-08-14
PCT/EP2003/050379 WO2004016619A1 (en) 2002-08-14 2003-08-14 Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors

Publications (2)

Publication Number Publication Date
NO20051291L true NO20051291L (no) 2005-05-18
NO331846B1 NO331846B1 (no) 2012-04-23

Family

ID=31725465

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20051291A NO331846B1 (no) 2002-08-14 2005-03-14 Bredspektrede, substituerte oksindol-sulfonamid HIV-proteaseinhibitorer.

Country Status (18)

Country Link
US (1) US7199148B2 (no)
EP (1) EP1546153A1 (no)
JP (1) JP4681296B2 (no)
KR (1) KR100994759B1 (no)
CN (1) CN1688586B (no)
AP (1) AP2126A (no)
AU (1) AU2003262574B2 (no)
BR (1) BR0305771A (no)
CA (1) CA2493940C (no)
EA (1) EA010486B1 (no)
HR (1) HRP20050606B1 (no)
IL (1) IL166462A (no)
MX (1) MXPA05001792A (no)
NO (1) NO331846B1 (no)
NZ (1) NZ538714A (no)
PL (1) PL375307A1 (no)
WO (1) WO2004016619A1 (no)
ZA (1) ZA200501223B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003057173A2 (en) * 2002-01-07 2003-07-17 Sequoia Pharmaceuticals Broad spectrum inhibitors
AU2005222435B2 (en) * 2004-03-11 2012-03-15 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
EP2422780A1 (en) * 2004-05-07 2012-02-29 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
TWI482775B (zh) 2008-09-01 2015-05-01 Tibotec Pharm Ltd 用於製備（３ｒ，３ａｓ，６ａｒ）－六氫呋喃并〔２，３－ｂ〕呋喃－３－基（１ｓ，２ｒ）－３－〔〔（４－胺基苯基）磺醯基〕（異丁基）胺基〕－１－苯甲基－２－羥基丙基胺基甲酸酯之方法
US8921415B2 (en) 2009-01-29 2014-12-30 Mapi Pharma Ltd. Polymorphs of darunavir
PL2528923T3 (pl) 2010-01-28 2015-01-30 Mapi Pharma Ltd Sposób wytwarzania darunawiru i pochodnych darunawiru
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
WO2012092168A1 (en) * 2010-12-27 2012-07-05 Purdue Research Foundation Fused 6,5 bicyclic ring system p2 ligands, and methods for treating hiv
WO2012092188A1 (en) * 2010-12-27 2012-07-05 Ghosh Arun K Hydrogen bond forming p1 ligands and methods for treating hiv
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
JPWO2016039403A1 (ja) * 2014-09-11 2017-06-29 塩野義製薬株式会社 持続性ｈｉｖプロテアーゼ阻害剤

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
WO1995006030A1 (en) 1993-08-24 1995-03-02 G.D. Searle & Co. Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors
PH30929A (en) 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
SG48049A1 (en) 1993-10-01 1998-04-17 Astra Ab Process i
WO1996022287A1 (en) * 1995-01-20 1996-07-25 G.D. Searle & Co. Bis-sulfonamide hydroxyethylamino retroviral protease inhibitors
US5756533A (en) 1995-03-10 1998-05-26 G.D. Searle & Co. Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
US5705500A (en) 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US6150556A (en) 1995-03-10 2000-11-21 G. D. Dearle & Co. Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
JP4124818B2 (ja) 1995-03-10 2008-07-23 ジー．ディー．サール アンド カンパニー ヘテロシクロカルボニルアミノ酸ヒドロキシエチルアミノスルホンアミドレトロウイルスプロテアーゼインヒビター
US5753660A (en) 1995-11-15 1998-05-19 G. D. Searle & Co. Substituted sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
DE69726729T2 (de) 1996-05-20 2004-12-02 Janssen Pharmaceutica N.V. Fungizide mittel mit verbesserter bioverfügbarkeit
EE03904B1 (et) 1997-03-26 2002-12-16 Janssen Pharmaceutica N.V. Graanul, farmatseutiline doseerimisvorm, graanulite valmistamismeetod ja ravimiga kaetud graanulid
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
TR200002402T2 (tr) 1997-12-24 2001-01-22 Vertex Pharmaceuticals Incorporated Aspartil proteaz inhibitörü ön-ilaçlar.
AP1717A (en) * 1998-06-19 2007-01-30 Vertex Pharma Sulfonamide inhibitors of aspartyl protease.
AU4828199A (en) 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
DE69943266D1 (de) 1998-06-23 2011-04-21 Trustees For The University Of Illinois Board Of Arzneimittel zur behandlung von hiv-infizierten säugetieren
AU2001249397A1 (en) * 2000-03-24 2001-10-08 Cor Therapeutics, Inc. Oxindole inhibitors of factor xa

Also Published As

Publication number Publication date
CA2493940C (en) 2011-11-22
CN1688586B (zh) 2012-05-09
MXPA05001792A (es) 2005-04-25
HRP20050606B1 (hr) 2014-04-25
NZ538714A (en) 2007-03-30
NO331846B1 (no) 2012-04-23
CA2493940A1 (en) 2004-02-26
ZA200501223B (en) 2006-07-26
AU2003262574B2 (en) 2009-07-09
AP2005003245A0 (en) 2005-03-31
IL166462A0 (en) 2006-01-15
JP4681296B2 (ja) 2011-05-11
JP2005537305A (ja) 2005-12-08
KR100994759B1 (ko) 2010-11-16
PL375307A1 (en) 2005-11-28
EA200500350A1 (ru) 2005-08-25
BR0305771A (pt) 2004-10-05
EA010486B1 (ru) 2008-10-30
CN1688586A (zh) 2005-10-26
US20060058368A1 (en) 2006-03-16
IL166462A (en) 2012-04-30
EP1546153A1 (en) 2005-06-29
WO2004016619A1 (en) 2004-02-26
KR20050042141A (ko) 2005-05-04
AP2126A (en) 2010-06-03
AU2003262574A1 (en) 2004-03-03
HRP20050606A2 (en) 2006-02-28
US7199148B2 (en) 2007-04-03

Similar Documents

Publication Publication Date Title
NO20051291L (no) Bredspektrede substituerte oksindol-sulfonamid HIV-proteaseinhibitorer
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
CO6190525A2 (es) Fosfoindoles enantiomericamente puros como inhibidores de vih
ECSP20044709A (es) Inhibidores de sarcómero cardíaco
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
NO20082562L (no) Heterocyklisk forbindelse med inhiberende aktivitet pa 11- -hydroksysteroid-dehydrogenase type 1
AR052887A1 (es) Derivados de tiazol, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para tratar enfermedades mediadas por la inhibicion de la protein quinasa
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
DE60103133D1 (de) Imidazol-2-carbonsäureamid derivate als raf kinase inhibitoren
HUP0402454A2 (hu) Szubsztituált kinazolinszármazékok mint az aurora kinázok inhibitorai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EA200200769A1 (ru) Ингибиторы гиразы и их применение
DK1313695T3 (da) Estere af 5-aminolevulinsyre som fotosensibiliserende midler i fotokemoterapi
NO20091889L (no) Inhibitorer av spiroketon acetyl-CoA karboksylase
ATE556058T1 (de) 1-(2h)-isochinolonderivat
HUP0300359A2 (hu) 2-Benzotiazolil-karbamid-származékok és protein kináz inhibitorként történő felhasználásuk és ezeket tartalmazó gyógyszerkészítmények
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
UY32004A (es) Derivados de carbamatos de alquiltiazoles, su preparación y su aplicación en terapéutica
ECSP21016009A (es) Inhibidores de sarcómeros cardíacos
NO20091301L (no) Nye aminopyridinderivater med aurora A selektiv inhiberende aktivitet
NO20033584D0 (no) Bredspektrede 2-(substituert-amino)-benzotiazolsulfonamid-hiv- proteaseinhibitorer
ATE466838T1 (de) Sulfonamid-derivate als lebercarnitin-palmitoyl- transferase-hemmer
ES2632798T3 (es) Uso de derivados de cumarina para la preparación de fármacos de tratamiento de enfermedades de la piel
EA200602136A1 (ru) Комбинации замещенных 1-фенил-1,5-дигидропиридо[3,2-b] индол-2-онов и других ингибиторов вич
RU2009102270A (ru) Производные тиазолилмочевины в качестве ингибиторов фосфатидилинозитол-3-киназы
CU20230009A7 (es) Composiciones farmacéuticas que comprenden compuestos derivados de (r)-n-(5-(3-hidroxipirrolidin-1-il)-2-morfolinooxazolo[4,5-b]piridin-6- il)-2-(2-metilpiridin-4-il) oxazol-4 -carboxamida, útiles como inhibidores de irak

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees